ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Rituximab"

  • Abstract Number: 0005 • ACR Convergence 2021

    Maturation and Dysfunction of Autoreactive B Cell Clones in Tissues of Patients with Sjögren’s Syndrome

    Mathijs Broeren1, Giulia Balzaretti2, Jing Wang3, Patricia Groenen1, Barbera van Schaik4, Tim Chataway3, Charlotte Kaffa1, Sander Bervoets1, Konnie Hebeda1, Gergana Bounova5, Ger Pruijn1, Tom Gordon3, Niek De Vries6 and Rogier Thurlings7, 1Radboud University Medical Center, Nijmegen, Netherlands, 2Amsterdam, Netherlands, 3Flinders University, Adelaide, Australia, 4Amsterdam University Medical Centers, Amsterdam, Netherlands, 5Enpicom BV, Den Bosch, Netherlands, 6Amsterdam UMC, Amsterdam, Netherlands, 7Radboud University Medical Centre, Nijmegen, Netherlands

    Background/Purpose: Sjögren's syndrome (SjS) involves chronic inflammation of exocrine glands that can be complicated by extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT). We…
  • Abstract Number: 0321 • ACR Convergence 2021

    Sequential Administration of Belimumab and Rituximab in Primary Sjögren’s Syndrome Reduces Minor Salivary Gland–Resident B Cells and Delays B-Cell Repopulation in Circulation

    André van Maurik1, David Gardner2, Saba Nayar2, Charlotte Smith2, Kenneth Clark1, Prafull Mistry1, Rajesh Punwaney3, David Roth3, Robert Henderson1, Xavier Mariette4 and Francesca Barone2, 1GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, 2University of Birmingham, College of Medical and Dental Sciences, Birmingham, United Kingdom, 3GlaxoSmithKline, Collegeville, PA, 4Université Paris- Saclay, Rheumatology, Paris, France

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is characterized by B-cell hyperactivity and elevated serum and saliva B-lymphocyte stimulator (BLyS) levels.1 Sequential administration of belimumab (BEL; anti-BLyS)…
  • Abstract Number: 0416 • ACR Convergence 2021

    Pharmacological Response of Rituximab Based on Dose Intensity in Maintenance Therapy of ANCA-Associated Vasculitis

    Jason Springer1 and Ryan Funk2, 1Vanderbilt University Medical Center, Franklin, TN, 2University of Kansas Medical Center, Kansas City, KS

    Background/Purpose: Rituximab (RTX) has demonstrated efficacy in maintenance therapy in ANCA-associated vasculitis. However, different dosing protocols have been used in clinical trials and there is…
  • Abstract Number: 0649 • ACR Convergence 2021

    Optimizing SARS-CoV-2 Vaccine Timing in Rituximab-Treated Patients with Autoimmune Rheumatic Diseases: A Quality Improvement Intervention

    Daniel Magliulo1, Stefanie Wade2 and Vasileios Kyttaris3, 1Beth Israel Deaconess Medical Center, Boston, MA, 2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3BIDMC, Boston, MA

    Background/Purpose: Experience with rituximab (RTX) in autoimmune rheumatic disease (AIRD) has shown a clear association with hypogammaglobulinemia, serious infections, and impaired humoral response to certain…
  • Abstract Number: 0964 • ACR Convergence 2021

    Rituximab Treatment Dramatically Reduces Neutralizing Humoral Response to mRNA SARS-COV-2 Vaccines in Patients with Autoimmune Diseases

    Samuel Bitoun1, Julien Henry2, Christelle Vauloup Fellous3, Raphaele Seror4, Lina Mouna3, Candie Joly5, Delphine Desjardins5, Marie Bitu5, Roger Le Grand6, Anne-Marie Roque Afonso3 and Xavier Mariette7, 1Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Paris, France, 2Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Le Plessis Robinson, France, 3AP–HP, Hôpital Paul-Brousse, Department of Virology, University Paris Saclay, INSERM U1193,, Villejuif, France, 4Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184, FHU CARE FHU CARE, Le kremlin Bicetre, France, 5Paris-Saclay University, Inserm UMR 1184, FHU CARE, CEA, Le Kremlin Bicêtre, France, 6UMR1184, IDMIT Department, Université Paris-Saclay, Inserm, CEA, Fontenay Aux Roses, France, 7Université Paris- Saclay, Rheumatology, Paris, France

    Background/Purpose: The global COVID-19 pandemic is starting to be controlled by massive vaccination. Some immunosuppressed patients have already paid a high price to the pandemic…
  • Abstract Number: 1232 • ACR Convergence 2021

    Synovial Tissue Lymphoid Aggregates Are Associated with Response to Rituximab Therapy in Rheumatoid Arthritis Patients

    Matthew Turk1, Candice Low2, Carl Orr3, Richard Conway4, Kieran Murray5, Ursula Fearon6 and Douglas Veale7, 1St. Vincents University Hospital, Dublin, Ireland, 2St. Vincent's University Hospital, Dublin, Ireland, 3St Vincent's Hospital, Dublin, Ireland, 4St. James's University Hospital, Dublin, Ireland, 5Saint Vincent's University Hospital, Dublin, Ireland, 6Trinity College Dublin, Dublin, Ireland, 7University College Dublin, Dublin, Ireland

    Background/Purpose: Activated B lymphocytes and plasma cells are implicated in the pathogenesis of rheumatoid arthritis (RA). The anti-CD20 monoclonal antibody therapy (Rituximab) is an effective…
  • Abstract Number: 1445 • ACR Convergence 2021

    Association Between Baseline Use of Rituximab and COVID-19 Outcomes in Patients with Rheumatoid Arthritis (RA)

    Namrata Singh1, Chen Hu2, Vithal Madhira2, Kate Fitzgerald2, Timothy Bergquist3, Kayte Anderson2, Amy Olex4, Rena Patel5 and Jasvinder Singh6, 1University of Washington, Bellevue, WA, 2Johns Hopkins, Baltimore, MD, 3Sage Bionetworks, Seattle, WA, 4Virginia Commonwealth University, Richmond, VA, 5UW, Seattle, WA, 6University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Patients with Rheumatoid arthritis (RA) are at a potentially increased risk of SARS-CoV-2 infection, and immunosuppressive or biologic drugs used to treat RA might…
  • Abstract Number: 1562 • ACR Convergence 2021

    B Cell Reconstitution Is Strongly Associated with COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Treated with Rituximab

    Sarah Jinich, Deanna Jannat-Khah and Robert Spiera, Hospital for Special Surgery, New York, NY

    Background/Purpose: Rituximab (RTX) has previously been shown to impair antibody response to vaccines such as influenza and streptococcus. Recently, diminished COVID-19 vaccine responsiveness in RTX…
  • Abstract Number: 008 • 2020 Pediatric Rheumatology Symposium

    Incidence and Risk Factors of Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Pediatric Rheumatic Diseases

    Mei-Sing Ong1, Deborah Rothman 2 and Marc Natter 3, 1Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, 2Massachusetts General Hospital, Springfield, 3Boston Children's Hospital, Boston

    Background/Purpose: B-cell depletion therapy has increasingly been used for the treatment of childhood-onset rheumatic diseases. Previous studies investigating whether rituximab results in increased infections have…
  • Abstract Number: 068 • 2020 Pediatric Rheumatology Symposium

    Development of CARRA Consensus Treatment Plans for Severe ANCA-associated Vasculitis – Final CARRA-wide Consensus

    Linda Wagner-Weiner 1, Vidya Sivaraman 2, Karen James 3, Eric Yen 4, Kathleen O'Neil 5, Dana Gerstbacher 6, Ann Marie Szymanski7, Kimberly Morishita 8 and David Cabral 9 for the CARRA investigators, 1University of Chicago, Chicago, Illinois, 2Division of Rheumatology, Nationwide Children's Hospital, Bexley, 3University of Utah, 84113, Utah, 4UCLA, Los Angeles, California, 5University of Indiana School of Medicine, Indianapolis, Indiana, 6Stanford University School of Medicine, Palo Alto, California, 7Tampa, Florida, 8University of British Columbia - Vancouver, Vancouver, British Columbia, Canada, 9BC Children's Hospital and University of British Columbia, Vancouver, British Columbia, Canada

    Background/Purpose: Randomized trials for pediatric ANCA-associated vasculitis (ped-AAV) have not been feasible because of its rarity, therefore adult treatment strategies are usually adapted for children.…
  • Abstract Number: 113 • 2020 Pediatric Rheumatology Symposium

    Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease

    Alexis Wilsey1, Heather Van Mater 2 and Laura Cannon 2, 1Durham, 2Duke University, Durham

    Background/Purpose: Rituximab is standard therapy in treating autoimmune brain disease (ABD) including refractory autoimmune encephalitis (AE) and Neuromyelitis Optica Spectrum Disease (NMOSD). Recommendations for continuing…
  • Abstract Number: 143 • 2020 Pediatric Rheumatology Symposium

    Immunological Profiles Following Treatment with Rituximab in Autoimmune Disease

    Laura Cannon 1, Stephanie Johannes1 and Jeffrey Dvergsten 2, 1Duke University, Durham, 2Duke University Hospital, Hillsborough

    Background/Purpose: Autoimmune diseases, including systemic lupus erythematosus (SLE), juvenile dermatomyositis (JDM), and Autoimmune Encephallitis (AE) arise due to dysregulation of the immune system and a…
  • Abstract Number: 2634 • 2019 ACR/ARP Annual Meeting

    ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients

    Laura van Dam1, Ebru Dirikgil 2, Edwin Bredewold 2, Argho Ray 2, Ton Rabelink 2, Cees van Kooten 2 and Onno Teng 2, 1LUMC, Leiden, Zuid-Holland, Netherlands, 2LUMC, Leiden, Netherlands

    Background/Purpose: Recent studies have demonstrated that in patients with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) with successful remission-induction (RI) after cyclophosphamide (CYC), maintenance treatment with…
  • Abstract Number: 2902 • 2019 ACR/ARP Annual Meeting

    The Use and Safety of Rituximab in Connective Tissue Disease Associated Interstitial Lung Disease

    Christopher Mesa1, Snehaja Yadlapati 1 and Myriam Guevara 2, 1Louisiana State University Health Science Center, New Orleans, LA, 2Louisiana State University School of Medicine, New Orleans

    Background/Purpose: Interstitial Lung Disease (ILD) is the most common lung manifestation in Connective Tissue Diseases (CTD). It is present in most types of CTD, such…
  • Abstract Number: 2911 • 2019 ACR/ARP Annual Meeting

    A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response – Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy

    Frances humby 1, Maya H. Buch 2, Patrick Durez 3, Myles Lewis 1, Michele Bombardieri 1, Hasan Rizvi 4, Stephen Kelly 4, Liliane Fosatti 1, Rebecca Hands 1, Giovanni Giorli 1, Arti Mahto 1, Carlomaurizio Montecucco 5, Bernard Lauwerys 6, Vasco Romao 7, Arthur Pratt 8, Serena Bugatti 9, Nora Ng 10, Felice Rivellese 1, Pauline Ho 11, Mattia Bellan 12, Mattia Congia 13, Patrick Verschueren 14, Pier Paolo Sainaghi 12, Nagui Gendi 15, Bhaskar Dasgupta 16, Alberto Cauli 17, Piero Reynolds 18, Juan Cañete 19, Robert J. Moots 20, Peter Taylor 21, Christopher Edwards 22, John Isaacs 8, Peter Sasieni 23, João Eurico Fonseca 24, Ernest Choy 25 and Costantino Pitzalis26, 1Queen Mary University of London, London, United Kingdom, 2University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, 3Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, UCL Saint-Luc, Brussels, Belgium, 4Barts Health NHS Trust, London, United Kingdom, 5Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, 6University of Louvain, Louvain, Belgium, 7University of Lisbon, Lisbon, Portugal, 8University of Newcastle, Newcastle, United Kingdom, 9University of Pavia, Pavia, Italy, 10Guys and St Thomas NHS Trust, London, United Kingdom, 11University of Manchester, Manchester, United Kingdom, 12University of Novara, Novara, Italy, 13University of Cagliari, Cagliari, Italy, 14University of Leuven, Leuven, Belgium, 15Basildon Hospital NHS Trust, Basildon, United Kingdom, 16Southend University Hospital, NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, 17Rheumatology Unit, University Clinic AOU and University of Cagliari, Cagliari, Italy, 18Homerton University NHS Trust, London, United Kingdom, 19Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, 20Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, 21University of Oxford, Oxford, United Kingdom, 22University of Southampton, Southampton, United Kingdom, 23Kings College London, London, United Kingdom, 24Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; Centro Académico de Medicina de Lisboa; Lisbon, Portugal., Lisbon, Portugal, 25Cardiff University School of Medicine, Cardiff, United Kingdom, 26Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom

    Background/Purpose: Although biologic therapies have transformed the outlook for rheumatoid arthritis (RA), the lack of a major treatment response in over 50% of patients, the…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences